Published in Front Neurol on June 12, 2014
Future scenarios for levodopa-induced dyskinesias in Parkinson's disease. Front Neurol (2015) 0.75
Morphometric changes in the reward system of Parkinson's disease patients with impulse control disorders. J Neurol (2015) 0.75
Magnetic resonance imaging and tensor-based morphometry in the MPTP non-human primate model of Parkinson's disease. PLoS One (2017) 0.75
Voxel-based morphometry--the methods. Neuroimage (2000) 34.79
Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging (2002) 22.40
Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain (1991) 8.16
A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med (2000) 6.21
Simultaneous PET-MRI: a new approach for functional and morphological imaging. Nat Med (2008) 4.54
Plasticity in gray and white: neuroimaging changes in brain structure during learning. Nat Neurosci (2012) 3.92
Treatment of parkinsonism with levodopa. Arch Neurol (1969) 3.76
Dopamine receptor signaling. J Recept Signal Transduct Res (2004) 3.47
Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat Neurosci (2003) 3.25
Simultaneous MR/PET imaging of the human brain: feasibility study. Radiology (2008) 2.65
Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain (2007) 2.49
Training of working memory impacts structural connectivity. J Neurosci (2010) 2.36
Focal decline of cortical thickness in Alzheimer's disease identified by computational neuroanatomy. Cereb Cortex (2004) 2.36
Lithium, gray matter, and magnetic resonance imaging signal. Biol Psychiatry (2012) 2.19
L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur J Neurosci (1998) 2.10
Methodology of brain perfusion imaging. J Magn Reson Imaging (2001) 1.99
Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB(1) and TRPV1 receptors. Exp Neurol (2007) 1.85
Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol (2006) 1.82
Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia. Ann Neurol (2010) 1.80
Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Neuropharmacology (2005) 1.75
Molecular mechanisms of L-DOPA-induced dyskinesia. Nat Rev Neurosci (2008) 1.71
Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann Neurol (2005) 1.65
Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats. Exp Neurol (2011) 1.64
Metabotropic glutamate receptors in the basal ganglia motor circuit. Nat Rev Neurosci (2005) 1.57
Contrasting effects of haloperidol and lithium on rodent brain structure: a magnetic resonance imaging study with postmortem confirmation. Biol Psychiatry (2012) 1.56
L-DOPA activates ERK signaling and phosphorylates histone H3 in the striatonigral medium spiny neurons of hemiparkinsonian mice. J Neurochem (2009) 1.53
Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias. Brain (2006) 1.53
Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap. Lancet Neurol (2010) 1.50
Maze training in mice induces MRI-detectable brain shape changes specific to the type of learning. Neuroimage (2010) 1.50
Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. J Neurosci (2002) 1.40
Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease. Br J Pharmacol (2011) 1.39
A critical interaction between NR2B and MAGUK in L-DOPA induced dyskinesia. J Neurosci (2006) 1.34
Rhythm-specific modulation of the sensorimotor network in drug-naive patients with Parkinson's disease by levodopa. Brain (2013) 1.29
Increased prefrontal volume in PD with levodopa-induced dyskinesias: a voxel-based morphometry study. Mov Disord (2011) 1.27
The relation between brain iron and NMR relaxation times: an in vitro study. Magn Reson Med (1996) 1.27
Involvement of cannabinoid receptors in the regulation of neurotransmitter release in the rodent striatum: a combined immunochemical and pharmacological analysis. J Neurosci (2005) 1.26
Nondopaminergic mechanisms in levodopa-induced dyskinesia. Mov Disord (2005) 1.25
Prefrontal alterations in Parkinson's disease with levodopa-induced dyskinesia during fMRI motor task. Mov Disord (2011) 1.23
Parkinson's disease: levodopa-induced dyskinesia and signal transduction. FEBS J (2008) 1.22
Patterns of cortical thickness and surface area in early Parkinson's disease. Neuroimage (2010) 1.21
Levodopa in the treatment of Parkinson's disease. Eur J Neurol (2009) 1.21
Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. Brain (2008) 1.19
Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models. Neurology (2001) 1.15
Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation. J Neural Transm (Vienna) (2011) 1.12
cAMP response element-binding protein is required for dopamine-dependent gene expression in the intact but not the dopamine-denervated striatum. J Neurosci (2001) 1.12
Glutamate NMDA receptor dysregulation in Parkinson's disease with dyskinesias. Brain (2011) 1.11
L-DOPA reverses the MPTP-induced elevation of the arrestin2 and GRK6 expression and enhanced ERK activation in monkey brain. Neurobiol Dis (2005) 1.10
AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials. Mov Disord (2011) 1.10
Differential actions of serotonin, mediated by 5-HT1B and 5-HT2C receptors, on GABA-mediated synaptic input to rat substantia nigra pars reticulata neurons in vitro. J Neurosci (1996) 1.09
Expression and function of CB1 receptor in the rat striatum: localization and effects on D1 and D2 dopamine receptor-mediated motor behaviors. Neuropsychopharmacology (2007) 1.08
Transcriptome analysis in a rat model of L-DOPA-induced dyskinesia. Neurobiol Dis (2004) 1.07
Altered D(1) dopamine receptor trafficking in parkinsonian and dyskinetic non-human primates. Neurobiol Dis (2007) 1.06
Signal transduction interactions between CB1 cannabinoid and dopamine receptors in the rat and monkey striatum. Neuropharmacology (2001) 1.06
Evidence for a role of the 5-HT1B receptor and its adaptor protein, p11, in L-DOPA treatment of an animal model of Parkinsonism. Proc Natl Acad Sci U S A (2008) 1.06
Chronic L-DOPA treatment increases extracellular glutamate levels and GLT1 expression in the basal ganglia in a rat model of Parkinson's disease. Eur J Neurosci (2004) 1.05
Effect of chronic antipsychotic treatment on brain structure: a serial magnetic resonance imaging study with ex vivo and postmortem confirmation. Biol Psychiatry (2010) 1.05
Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with L-dopa-induced dyskinesia. Proc Natl Acad Sci U S A (2010) 1.05
Transcription factors involved in the pathogenesis of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease. Amino Acids (2002) 1.05
Buspirone in levodopa-induced dyskinesias. Clin Neuropharmacol (1994) 1.04
Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study. Neurology (2001) 1.03
Long term treatment and disease severity change brain responses to levodopa in Parkinson's disease. J Neurol Neurosurg Psychiatry (2003) 1.03
Cortical motor overactivation in parkinsonian patients with L-dopa-induced peak-dose dyskinesia. Brain (1998) 1.03
Brain T1 intensity changes after levodopa administration in healthy subjects: a voxel-based morphometry study. Br J Clin Pharmacol (2006) 1.03
Topology-corrected segmentation and local intensity estimates for improved partial volume classification of brain cortex in MRI. J Neurosci Methods (2010) 1.02
In vivo evidence for a differential contribution of striatal and nigral D1 and D2 receptors to L-DOPA induced dyskinesia and the accompanying surge of nigral amino acid levels. Neurobiol Dis (2011) 1.01
Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease. Neurobiol Dis (2003) 1.01
In vivo voxel based morphometry: detection of increased hippocampal volume and decreased glutamate levels in exercising mice. Neuroimage (2012) 1.01
Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson's disease. CNS Drugs (2012) 1.01
Simultaneous PET-MRI reveals brain function in activated and resting state on metabolic, hemodynamic and multiple temporal scales. Nat Med (2013) 1.00
Differential and distributed effects of dopamine neuromodulations on resting-state network connectivity. Neuroimage (2013) 1.00
Enhanced preproenkephalin-B-derived opioid transmission in striatum and subthalamic nucleus converges upon globus pallidus internalis in L-3,4-dihydroxyphenylalanine-induced dyskinesia. Biol Psychiatry (2006) 1.00
Neuroimaging evidence of major morpho-anatomical and functional abnormalities in the BTBR T+TF/J mouse model of autism. PLoS One (2013) 1.00
Tardive dyskinesia is caused by maladaptive synaptic plasticity: a hypothesis. Mov Disord (2012) 0.99
Dynorphin exerts both postsynaptic and presynaptic effects in the Globus pallidus of the rat. J Neurophysiol (2000) 0.98
New ideas on the origin of L-dopa-induced dyskinesias: age, genes and neural plasticity. Trends Pharmacol Sci (2005) 0.98
In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with\ increased motor disability. J Pharmacol Exp Ther (2006) 0.96
Voxel based morphometry reveals specific gray matter changes in primary dystonia. Mov Disord (2007) 0.95
Levodopa-induced dyskinesia is strongly associated with resonant cortical oscillations. J Neurosci (2012) 0.94
mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys. Neurobiol Aging (2007) 0.93
Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Mov Disord (2002) 0.93
Differential effect of selective D-1 and D-2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- exposed monkeys. J Pharmacol Exp Ther (1993) 0.92
Evolution of extra-nigral damage predicts behavioural deficits in a rat proteasome inhibitor model of Parkinson's disease. PLoS One (2011) 0.92
rTMS of supplementary motor area modulates therapy-induced dyskinesias in Parkinson disease. Neurology (2005) 0.91
Animal models of Parkinson's disease and L-dopa induced dyskinesia: how close are we to the clinic? Psychopharmacology (Berl) (2007) 0.91
Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia. Mov Disord (2013) 0.91
Impact of L-DOPA treatment on regional cerebral blood flow and metabolism in the basal ganglia in a rat model of Parkinson's disease. Neuroimage (2012) 0.91
Levodopa-induced dyskinesia in Parkinson's disease. J Neural Transm (Vienna) (2004) 0.90
Dopamine D(1) receptor expression in human basal ganglia and changes in Parkinson's disease. Brain Res Mol Brain Res (2001) 0.90
Striatal histone modifications in models of levodopa-induced dyskinesia. J Neurochem (2008) 0.89
Serotonin 1B receptor stimulation reduces D1 receptor agonist-induced dyskinesia. Neuroreport (2009) 0.89
Morphological changes in serotoninergic neurites in the striatum and globus pallidus in levodopa primed MPTP treated common marmosets with dyskinesia. Neurobiol Dis (2010) 0.89
Effect of dopamine denervation and dopamine agonist administration on serine phosphorylation of striatal NMDA receptor subunits. Brain Res (1999) 0.89
Morphological brain plasticity induced by musical expertise is accompanied by modulation of functional connectivity at rest. Neuroimage (2014) 0.89
Reduced cortical volume and elevated astrocyte density in rats chronically treated with antipsychotic drugs-linking magnetic resonance imaging findings to cellular pathology. Biol Psychiatry (2013) 0.89
Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson's disease: implications for the early use of COMT inhibitors. Neurology (2000) 0.88
Non-invasive evaluation of nigrostriatal neuropathology in a proteasome inhibitor rodent model of Parkinson's disease. BMC Neurosci (2010) 0.88
Comparative effects of acute or chronic administration of levodopa to 6-OHDA-lesioned rats on the expression and phosphorylation of N-methyl-D-aspartate receptor NR1 subunits in the striatum. Neurochem Res (2009) 0.88
Alterations in cortical and basal ganglia levels of opioid receptor binding in a rat model of l-DOPA-induced dyskinesia. Neurobiol Dis (2001) 0.88
Levodopa reinstates connectivity from prefrontal to premotor cortex during externally paced movement in Parkinson's disease. Neuroimage (2013) 0.88
Preventing and controlling dyskinesia in Parkinson's disease--a view of current knowledge and future opportunities. Mov Disord (2008) 0.87